corporate presentation - ceaproceapro.com/.../2015/02/ceapro-presentation_february-2015.pdf ·...
TRANSCRIPT
Forward Looking Statements
This presentation contains forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of product development and launches. Although the company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company’s expectations are correct.
All forward-looking statements are expressly qualified by this Cautionary Statement.
2
Overview
• Canadian leader in botanical actives innovation and
bioprocessing o Proprietary plant extraction based manufacturing process
o Active ingredients for health care and cosmetic industries
• Two active ingredients currently used in household name
products - Cosmetics & Personal Care o Beta Glucan
o Avenanthramides
• De-risked business model and robust growth strategy
support potential for significant market expansion and
revenue generation
• Near-term potential to expand into nutraceutical, OTC and
Pharma markets
3
The identification, extraction
and purification of active
compounds from natural
sources…
…which allows us to create
innovative ingredients for the
personal and healthcare
industries
…We are a Green Company!
Ceapro’s Core Expertise
4
Proprietary plant extraction based manufacturing
5
Lupinus angustifolia
And
Avena sativa
Beta Glucan Avenanthramides
Unique Bioprocessing Expertise
• Ability to isolate and purify
specific molecules from a wide
range of botanical sources
• Prototype extracts are then
prepared for bio-screening or in
vivo testing
• Unique drying (heat-free) technology for sensitive compounds
• Commercialized unique bio-actives from several botanical sources
• Ability to take concept to commercialization in a relatively short
period of time
6
CNC before and after PGX drying
0.5 g CNC Spray Dried
0.5 g CNC PGX Dried
CNC AEROGEL Density : 0.006 g/cm3
• Production of biomaterials from different industries
Application of PGX-CNC
• Applications of PGX-CNC
• Wound healing, scaffolds
• Drug delivery
• Absorbants
• Composite-Plastics
• Paints
• PGX processing allows processing of high value biopolymers:
• Beta Glucan
• Chitosan
• Gum Arabic
• CNC
Market Sectors (Current & Future)
Cosmetics & Personal Care
• Anti-Inflammation
• Anti-Ageing
Pharma/OTC(Botanic Drugs)
• Wound Healing
• Metabolic Diseases
Nutraceuticals/Functional Foods
• Metabolic Diseases
10
Cosmetics - From Field to Formulation
11
Field
Identify
Unique
Plants
Research
Discover
Novel Functional
Actives
Manufacturing
Develop
Innovative
Processes
Consumer
Provide
Innovative
Products
Beta Glucan and Avenanthramides in Multiple Household Products
• Aveeno
• Jergens
• Lubriderm
• 3M –Nexcare
• KY Products
• Neutrogena
• Coppertone
• Dove
• Burt’s Bees
• The Body Shop
• Philosophy
• ROC
12
Beta Glucan
15
• Beta glucan is a soluble fibre found in the call walls of oat kernels
• Acts as a natural moisture barrier and film-forming agent
• Relieves and alleviates dry and itchy skin by replenishing and protecting the skin’s moisture barrier
• Provides hydration against the drying effects of the sun
• Smoothens wrinkles, reducing the visible signs of ageing
• Ceapro was the first to
demonstrate that high
molecular weight beta
glucan can penetrate human
skin.
• Dermatology applications
range from anti-ageing to
wound healing.
• New highly purified beta
glucan powder successfully
developed to address new
market demands/trends.
16
Beta Glucan in Cosmeceuticals
Natural Skin Restructuring Agent
• Proven to effectively reduces
fine lines & wrinkles
• Forms a natural barrier
protecting skin
• Wound healing agent – films
or gels
• Sustained release of active
agents requiring enhanced
percutaneous transportation
17
Avenanthramides
• Antihistamine and anti-
inflammatory properties
• Potential benefits in the
control of inflammation-
based diseases
18
Avenanthramides Clinically Proven in Cosmeceuticals
• 40% improvement in itch
perception after 1 week
• 62% of patients showed an
improvement in their skin
condition
Significant improvements in
erythema symptoms associated
in subjects with mild to
moderate atopic dermatitis
Subjects with atopy
• 89% of subjects saw
significant improvement in
itch after 1 week
• Continued improvement
after 4 weeks
19
Skin inflammation is a complex physiological process Beta glucan
• Accelerates tissue healing
• Deep hydrating agent
• Improves elasticity
• Natural film protective barrier
Avenanthramides
• Relief from itching (Pruritus)
• Reduces inflammation and swelling
• Reduces redness (Erythema)
Our Value Drivers – Advanced Skin Care
Beta glucan
Avenanthramides
20
Robust Growth Strategy
21
Cosmeceuticals
• Generate scientific data to support current product indications
• Pursue new indications for current product portfolio from research programs
• Develop new products in accordance with needs expressed by customers
• Improve manufacturing technologies
• Look for ability to develop co-products
Nutraceuticals
• Produce 2nd generations of current products (higher concentrations, powder versions, etc)
• Capture bigger margins
Pharmaceuticals
• Produce 3rd generations of current products (higher concentrations, powder versions, etc)
• Conduct formulation work and assess potential for pharmaceutical development
Beta Glucan in Nutraceuticals and Pharmaceuticals
• Potential reduction of cardiovascular and heart diseases risk
o Acts to decrease LDL and total cholesterol
• Proprietary beta glucan drug-delivery platform
o Shown to effectively penetrate into the skin, into the deep
layers as well as into the skin cells
o Uses ranging from wound care and therapy, to skin care
treatments that reduce the signs of aging
22
Avenanthramides in Nutraceuticals and Pharmaceuticals
• Avenanthramides shown to
attenuate exercise-induced
inflammation in animal studies
• Human clinical studies showed that
dietary avenanthramides
supplements significantly reduced
inflammation biomarkers in an
elderly population
• New process technology licensed
from Agriculture and Agri-Food
Canada (AAFC)
23
Value Drivers
Cosmeceuticals - Current and new indications-Base Business
Nutraceuticals - New product development-Near Term Catalyst
Pharmaceuticals - New products, new partnership discussions
Manufacturing Innovation - New processes, higher output, lower cost
24
New Bio-processing Facility
25
New 21,000 sq. ft. GMP Bio-processing Extraction
Facility in Edmonton, Alberta
• R&D
• Pilot Scale Capability
• Commercial Production
Value-Driving Milestones
26
2015 - H1 2015 - H2 2016 - H1 2016 - H2
New Manufacturing Facility
Commercial scale-up of dry powder technology platform
Ceapro in Nutraceuticals and Pharmaceuticals
Beta Glucan preclinical studies
Beta Glucan Pilot Phase
Avenanthramides Phase ½
Financial Profile - TSX-V: CZO
27
TSX-V: CZO Stock Ticker
$43,000,000 Market capitalization as of January 2, 2015
61,420,000 Common shares outstanding
$6,831,000 Total sales for the nine-month period ending September 2014
$4,000,000 Total amount of grant-based-funding raised to date
28
Financial Performance 2009-2013
-2000
0
2000
4000
6000
8000
2009 2010 2011 2012 2013
Revenue Income (loss) from Operations ($000)
29
Financial Performance First 9 months 2014 vs 2013 (in 000’s)
$0
$1 000
$2 000
$3 000
$4 000
$5 000
$6 000
$7 000
$8 000
2013 2014
Revenue Net Income
Recent Positive Momentum
30
$0,00
$0,10
$0,20
$0,30
$0,40
$0,50
$0,60
$0,70
$0,80
7-1-10 7-31-10 8-30-10 9-29-10 10-29-10 11-28-10 12-28-10
Pri
ce
Date
12/18 - Ceapro Enters
into Financing
Agreement
12/4 - Research Grant
from Alberta Innovates
Bio Solutions
11/26 - Research
Scientist Honored with
Scientific Achievement
11/14 - Third Quarter
2014 Financial Results
11/20 - Appoints
William W. Li, M.D. to
Board of Directors
7/30 - Second Quarter
2014 Financial Results
10/3 - Change of
Chairman of the Board
7/1/14 7/31/14 8/30/14 9/29/14 10/29/14 11/28/14 12/28/144
Ceapro is Poised for an Exciting 2015
A Solid Company!
Profitable
Highly-experienced, results-driven team
Operational efficiency
Solid innovative science/IP
Commercially accepted products
Expanded Marketing/Sales territories
Strong development Pipeline for long-term
sustainable growth
31